Unión Europea - español - EMA (European Medicines Agency)

accord healthcare s.l.u. - rivaroxaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - agentes antitrombóticos - prevención del tromboembolismo venoso (tev) en pacientes adultos sometidos a cirugía electiva de reemplazo de cadera o rodilla. tratamiento de la trombosis venosa profunda (tvp) y embolia pulmonar (pe), y la prevención de la recurrencia de la tvp y de la ep en los adultos. (see section 4. 4 for haemodynamically unstable pe patients. tratamiento de la trombosis venosa profunda (tvp) y embolia pulmonar (pe), y la prevención de la recurrencia de la tvp y de la ep en los adultos. (see section 4. 4 para hemodinámicamente inestable pe pacientes). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. tratamiento de la trombosis venosa profunda (tvp) y embolia pulmonar (pe), y la prevención de la recurrencia de la tvp y de la ep en los adultos. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 y 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. tratamiento de la trombosis venosa profunda (tvp) y embolia pulmonar (pe), y la prevención de la recurrencia de la tvp y de la ep en los adultos. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Unión Europea - español - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - agentes antitrombóticos - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

baxalta innovations gmbh - polvo y disolvente para soluciÓn inyectable - n/a (más de 4 pa) - n/a (más de 4 pa) n/a (más de 4 pa) - factores de la coagulacion ix, ii, vii y x en combinacion

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

agrovet market animal health - calcio, cloruro; vitamina a (retinol acetato); vitamina b12 (cianocobalamina); vitamina d3 (colecalciferol); vitamina e (a-tocoferol) - emulsión inyectable - calcio, cloruro 200 ml;vitamina a (retinol acetato) 5000000 u.i.;vitamina b12 (cianocobalamina) 12 mg;vitamina d3 (colecalciferol) 750000 u.i.;vitamina e (a-tocoferol) 500 u.i.;excipientes c.s.p , calcio, cloruro 200 ml; vitamina a (retinol acetato) 5000000 u.i.; vitamina b12 (cianocobalamina) 12 mg; vitamina d3 (colecalciferol) 750000 u.i.; vitamina e (a-tocoferol) 500 u.i.; excipientes c.s.p - estimulantes y reconstituyentes: estimulantes del apetito, metabolismo y hepáticos, reconstituyentes. minerales (macroelementos, microelementos y oligoelementos): asociados. vitaminas: solas. - camelidos, caninos, caprinos, equinos, felinos, ovinos, porcinos, vacunos - indicado para el tratamiento y prevención de las deficiencias de calcio y vitaminas presentes en la fórmula. condiciones de estrés, alteraciones metabólicas, pérdida de peso, anemia, anorexia, distrofia muscular; para promover el crecimiento en animales jóvenes, como tratamiento auxiliar en procesos infecciosos e/o infestaciones parasitarias, retardo de aparición del celo o para aumentar la fertilidad.